Page last updated: 2024-08-24

colestipol and pyrroles

colestipol has been researched along with pyrroles in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (33.33)	18.2507
2000's	4 (66.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abe, Y; Ballantyne, CM; Dunn, K; Gotto, AM; Hackman, A; Insull, W; Pownall, H; Smith, L	1
Bakker-Arkema, RG; Black, DM; Brown, AS; Campbell, CF; Guthrie, R; Henley, RW; Koren, M; McLain, R; Woo, W; Yellen, L	1
Bourbon, M; Knight, BL; Naoumova, RP; Neuwirth, CK; O'Neill, FH; Patel, DD; Soutar, AK; Taylor, GW; Thompson, GR	1
Susekov, AV	1
Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M	1
Angelin, B; Berglund, L; Borgström, B; Eggertsen, G; Ericsson, S; Eriksson, M; Lind, S; Olivecrona, H; Rudling, M	1

Reviews

2 review(s) available for colestipol and pyrroles

Article	Year
[Substantiation of increasing doses of statins in clinical practice]. Terapevticheskii arkhiv, 2001, Volume: 73, Issue:4 Topics: Adult; Aged; Angiography; Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Colestipol; Coronary Disease; Dogs; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Primates; Prospective Studies; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors	2001
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Archives of internal medicine, 2003, Mar-24, Volume: 163, Issue:6 Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome	2003

Article

Year

[Substantiation of increasing doses of statins in clinical practice].

Terapevticheskii arkhiv, 2001, Volume: 73, Issue:4

Topics: Adult; Aged; Angiography; Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Colestipol; Coronary Disease; Dogs; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Primates; Prospective Studies; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors

2001

Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.

Archives of internal medicine, 2003, Mar-24, Volume: 163, Issue:6

Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome

2003

Trials

2 trial(s) available for colestipol and pyrroles

Article	Year
Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. Journal of the American College of Cardiology, 1998, Volume: 32, Issue:3 Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Colestipol; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lovastatin; Male; Pyrroles; Simvastatin; Treatment Outcome	1998
Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. Arteriosclerosis, thrombosis, and vascular biology, 2001, Volume: 21, Issue:5 Topics: Anticholesteremic Agents; Atorvastatin; Cholestenones; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipoproteinemia Type II; Male; Mevalonic Acid; Middle Aged; Mutation; Pyrroles; Receptors, LDL; RNA, Messenger	2001

Article

Year

Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.

Journal of the American College of Cardiology, 1998, Volume: 32, Issue:3

Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Colestipol; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lovastatin; Male; Pyrroles; Simvastatin; Treatment Outcome

1998

Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia.

Arteriosclerosis, thrombosis, and vascular biology, 2001, Volume: 21, Issue:5

Topics: Anticholesteremic Agents; Atorvastatin; Cholestenones; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipoproteinemia Type II; Male; Mevalonic Acid; Middle Aged; Mutation; Pyrroles; Receptors, LDL; RNA, Messenger

2001

Other Studies

2 other study(ies) available for colestipol and pyrroles

Article	Year
Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation, 1996, Apr-01, Volume: 93, Issue:7 Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cell Adhesion Molecules; Colestipol; Drug Therapy, Combination; E-Selectin; Endothelium, Vascular; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Lovastatin; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Solubility; Vascular Cell Adhesion Molecule-1	1996
Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans. Arteriosclerosis, thrombosis, and vascular biology, 2004, Volume: 24, Issue:2 Topics: Adult; Atorvastatin; Bile Acids and Salts; Child; Cholesterol, LDL; Colestipol; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Heterozygote; Human Growth Hormone; Humans; Hyperlipoproteinemia Type II; Hypopituitarism; Lipoproteins, LDL; Male; Middle Aged; Pyrroles	2004

Article

Year

Levels of soluble cell adhesion molecules in patients with dyslipidemia.

Circulation, 1996, Apr-01, Volume: 93, Issue:7

Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cell Adhesion Molecules; Colestipol; Drug Therapy, Combination; E-Selectin; Endothelium, Vascular; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Lovastatin; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Solubility; Vascular Cell Adhesion Molecule-1

1996

Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans.

Arteriosclerosis, thrombosis, and vascular biology, 2004, Volume: 24, Issue:2

Topics: Adult; Atorvastatin; Bile Acids and Salts; Child; Cholesterol, LDL; Colestipol; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Heterozygote; Human Growth Hormone; Humans; Hyperlipoproteinemia Type II; Hypopituitarism; Lipoproteins, LDL; Male; Middle Aged; Pyrroles

2004